Fatigue is very common in multiple sclerosis (MS) and is often considered as its most disabling symptom. Over the last 20 years, an increasing number of studies have evaluated the pathogenetic bases of MS-related fatigue. Converging evidence from neurophysiology and neuroimaging research suggests that a dysfunction in a cortico-subcortical pathway, centered on thalamus, is involved in the pathogenesis of fatigue. However, type and significance of such dysfunction remain unknown, and some studies reported an increase in the activity and connectivity within the thalamic network, whereas others suggested its reduction. Hereby, we review the results of neuroimaging studies supporting the different hypotheses about the role of thalamic network in the pathophysiology of MS-related fatigue and discuss limitations and shortcomings of available data, highlighting the key challenges in the field and the directions for future research.
Introduction
Fatigue, defined as an overwhelming sense of lack of physical and/or mental energy, can affect up to 80% patients with multiple sclerosis (MS) and is often considered as its most disabling symptom. 1, 2 Fatigue is a poorly defined construct and, hence, difficult to measure and to define in the clinical practice and trials. 3 The MS International Federation identified two types of fatigue: (1) physical fatigue, characterized by muscle weakness and difficulties to perform daily tasks, and (2) cognitive fatigue, characterized by difficulties in thinking, concentration, and memory. 4 Fatigue is generally self-reported by patients, using questionnaires such as the Fatigue Severity Scale (FSS) 5 and the Modified Fatigue Impact Scale (MFIS). 6 Most frequently used pharmacological treatments for fatigue are amantadine, 4-aminopyridine, and modafinil. Non-pharmacological interventions include physical (e.g. aerobic exercises, resistance training, yoga, and tai-chi) and psychological/cognitive approaches (e.g. cognitive behavioral therapy, education programs, and mindfulness interventions). 3 However, evidence supporting the efficacy of these interventions is still preliminary and, sometimes, conflicting. This depends, at least in part, by our poor understanding of the processes underlying fatigue in MS and by the lack of validated and reproducible biomarkers (e.g. magnetic resonance imaging (MRI)).
Over the last 20 years, an increasing number of studies have evaluated the pathogenetic bases of MS-related fatigue. Converging evidence from neurophysiology 7, 8 and neuroimaging 9, 10 demonstrated that, in patients with MS, fatigue has a central origin and a dysfunction of the circuits between thalamus, basal ganglia, and cortex could be its main pathogenic substrate. Initially, many authors focused on areas of possible interest for motor fatigue (cortex and basal ganglia) that were easy to investigate with neuroimaging and neurophysiological tools. 7, 8, 11 However, the a priori choice of the region of interest (or seed region) has ignored the possible relevance of thalamus. More recently, thanks to the increasing interest in non-motor aspects of fatigue (i.e. cognitive and psychosocial) and the improved knowledge on the unique role of thalamus as a gateway for cortical areas and a relay between cortical and subcortical structures, 12 thalamus has progressively gained attention in the study of pathophysiology of MS-related fatigue. Overall, a dysfunction in a cortico-subcortical pathway, centered on thalamus, is involved in the pathogenesis of fatigue, but type and significance of such dysfunction remain unknown. Some studies reported an increase in the activity and connectivity of thalamic network, [13] [14] [15] [16] [17] whereas others suggested its reduction. [18] [19] [20] [21] [22] [23] Thus, the role of thalamus in the pathogenesis of fatigue remains largely controversial and different hypotheses have been proposed. In the past, original studies and reviews on fatigue in MS have evaluated different brain regions, while, in this review, we have decided to focus on the most promising area in the pathophysiology of MS-related fatigue, the thalamus. In the first part, we will briefly report on normal structure of the thalamus and on its impairment in MS. Then, we will describe the results of neuroimaging studies supporting different hypotheses about the role of thalamic network in the pathophysiology of MS-related fatigue (increased vs decreased activity). We will then unify existing data to discuss potential neuroanatomical mechanisms to explain how damage in (or outside of) the thalamus leads to symptoms of fatigue. Finally, we will discuss limitations and shortcomings of available data, highlighting the key challenges in the field and directions for future clinical trials and observational studies.
Thalamus: normal structure and function
The thalamus is the largest part of the diencephalon and is located between the third ventricle medially and the internal capsule laterally. The thalamus is extremely heterogeneous in its anatomical structure, functional connectivity, and neuroimaging appearance, and different classifications have been proposed (Figure 1 ).
Anatomically, the thalamus is divided into three regions (anterior, lateral, and medial) by the internal medullary lamina. Within each of these regions, there are nuclei with distinct connections (Figure 1(a) ). Other nuclei are located within the internal medullary lamina (intralaminar nuclei), and on the lateral aspect of the thalamus (reticular nucleus), out of the external medullary lamina. Finally, in the posterior area of the thalamus, there are the medial geniculate nucleus and the lateral geniculate nucleus.
Functionally, thalamic nuclei can be divided into three basic types: the relay nuclei, the association nuclei, and the non-specific nuclei 24 (Figure 1(b) ). Relay nuclei transmit information from the periphery to the cortex. Depending on the type of relayed information, they can be classified as follows: (1) sensory relay nuclei, acting as a gateway for sensory (somatosensory, visual, and auditory) inputs to reach different sensory cortical areas; 25 (2) motor relay nuclei, connecting subcortical motor structures, such as Anatomically (a), the thalamus is divided by the internal medullary lamina (green) into anterior nucleus (red), lateral region (containing lateral dorsal, ventral anterior, ventral lateral, ventral posterior, and lateral posterior nuclei, in blue), medial region (yellow), and posterior region (including pulvinar, medial geniculate, and lateral geniculate nuclei, in violet). Functionally (b), thalamic nuclei can be divided into relay nuclei, association nuclei, and nonspecific nuclei. Sensory relay nuclei send somatosensory (red), visual (pink), and auditory (green) inputs to different sensory cortical areas. Motor relay nuclei connect subcortical motor structures with cortical motor areas (blue). Limbic relay nuclei connect different structures of the limbic system (violet). The association nuclei receive input from the cerebral cortex and project back to the cerebral cortex (orange). The nonspecific nuclei send diffuse projections to the cerebral cortex. cerebellum and basal ganglia, with cortical motor areas such as primary motor and premotor cortex; 26 (3) limbic relay nuclei, connecting different structures of the limbic system such as mammillary bodies, cingulate cortex, and entorhinal cortex. 27 The association nuclei (e.g. pulvinar) receive input from the cerebral cortex and project back to the cerebral cortex and are supposed to regulate the activity of cortical association areas. 28 The nonspecific nuclei (e.g. intralaminar and midline thalamic nuclei) send diffuse projections to the cerebral cortex and are probably involved in general functions such as alertness and arousal. 29 Recent advances in neuroimaging techniques have enabled to identify, non-invasively, connections between the main thalamic nuclei and the cortex, which have strong correspondence with the anatomical and functional classification of thalamic nuclei derived from animal and human ex vivo studies. Using a probabilistic tractography algorithm, Behrens et al. 30 classified thalamic gray matter based on its connections with cortex and identified six main thalamic regions: frontal, occipital, parietal, temporal, precentral, and postcentral. This thalamic classification has shown high reproducibility within and between subjects 31 and has been confirmed on both functional MRI (fMRI) 32, 33 and diffusion tensor imaging (DTI). 34 
Thalamus in MS
Evidence of thalamic involvement in MS arises mainly from neuropathological and neuroimaging studies. Neuropathological studies 35, 36 have shown demyelination, inflammation, and neurodegeneration (i.e. neuronal loss, neuronal shrinkage, and axonal damage) in the thalamus. These findings have been confirmed in vivo using different neuroimaging techniques. Volumetric MRI studies showed thalamic atrophy, [37] [38] [39] since the very early stages of the disease, including clinically isolated syndrome (CIS), pediatric-onset MS, and radiologically isolated syndrome. 40 The development of advanced neuroimaging techniques, such as DTI, has allowed to detect microstructural alterations in its nuclei and in the white matter tracts toward cortical and subcortical areas, also in the absence of obvious thalamic atrophy. [41] [42] [43] [44] Taken together, neuroimaging and neuropathological studies suggest that thalamic damage in MS is common, occurs early, and can be related to either a primary damage in thalamus or a distant damage of afferent or efferent thalamic fibers, subsequently affecting the thalamus through mechanisms of Wallerian or transneuronal degeneration. 24 
Thalamus and fatigue in MS
The idea that thalamus could be involved in the pathophysiology of fatigue originally arises from studies showing structural and functional changes within the thalamus of fatigued MS patients. Different studies reported on thalamic atrophy along with basal ganglia and fronto-parietal cortex volume loss, in MS patients with fatigue. 45, 46 Moreover, advanced neuroimaging techniques showed indirect signs of demyelination and axonal loss in the thalamus of fatigued MS patients. 22, 47, 48 If a dysfunction in a cortico-subcortical pathway centered on thalamus is nowadays generally accepted as a determinant of fatigue in MS, contrasting results have been reported on type and significance of such dysfunction, with some studies reporting a reduction in the activity and connectivity of thalamic network, [18] [19] [20] [21] [22] [23] and others an increase. [13] [14] [15] [16] [17] Differences between these findings have produced two main hypotheses about the potential neuroanatomical mechanisms to explain how thalamic impairment leads to fatigue, as discussed below (Figure 2 ).
Reduced thalamic activity produces fatigue
Fatigue can arise from a global reduction in the activity of networks involving thalamus, basal ganglia, and cortex. Such reduction can be associated with measurable morphological changes (atrophy) in one or more parts of the network. Of note, functional connectivity may be increased between some areas of the network, as a compensatory strategy, while the global activity is globally reduced. This hypothesis is supported by studies showing a sustained reduction in thalamic functionality and connectivity in fatigued MS patients (Table 1) .
Roelcke et al. 21 preliminarily described reduced glucose metabolism on 18F-fluorodeoxyglucose positron emission tomography (PET) in the frontal cortex and in the basal ganglia of fatigued patients when compared with not-fatigued patients. A specific reduction in thalamic activity in fatigued MS patients was later described in another 18F-fluorodeoxyglucose PET study, 22 and also on MRI. 18, 20 In particular, Inglese et al. 20 found a significant association between fatigue severity and reduction in cerebral blood flow and volume in thalamus and basal ganglia using dynamic susceptibility contrast-enhanced T2*-weighted MRI, as from thalamic dysfunction and damage. Filippi et al. 18 demonstrated that activation of thalamus and sensory-motor cortical areas evoked by a simple motor task on fMRI was reduced in fatigued patients when compared with not-fatigued patients. These findings were recently confirmed by Rocca et al. 19 who showed, in a larger cohort, that fatigued patients have reduced activation in thalamus, basal ganglia, and fronto-temporal-parietal cortex during a simple motor task, followed by abnormal adaption over time. Similarly, Bonzano et al. 49 showed that fatigued MS patients presented with worse accuracy on repeated finger motor task and lower BOLD (blood-oxygen-level-dependent) signal, when compared with healthy subjects, that did not return to baseline level after rest.
Compensatory mechanisms to reduced thalamic activity and fatigue have been hypothesized. CruzGomez et al. 23 found that fatigued MS patients presented with decreased levels of resting-state MRI (rs-MRI) functional connectivity between areas related to sensory-motor functions (e.g. thalamus, cerebellum, brainstem, and frontal-parietal cortex), while not-fatigued patients displayed increased levels, as from compensatory mechanism reducing fatigue perception. Engstrom et al. 16 found that fatigued MS patients have weaker cortical-to-subcortical connections, but stronger cortical-to-cortical (left posterior parietal cortex and left dorsolateral prefrontal cortex) and subcorticalto-subcortical (right substantia nigra and left thalamus) connections, possibly also acting as a compensatory mechanism.
Fatigue is caused by a compensatory thalamic activity increase
In this hypothesis, fatigue arises from an increase in the activity of the networks involving thalamus, basal ganglia, and cortex, as a result of a compensatory mechanism that allows to maintain normal functioning but also produces fatigue. This hypothesis is supported by the results of a number of studies showing an increased activation in thalamus, basal ganglia, and fronto-parietal-occipital cortex in fatigued MS patients who performed a cognitive task during fMRI, when compared with controls or with not-fatigued patients (Table 2) .
Rocca et al. 13 found that patients experiencing fatigue after interferon-beta injections have an increased activation of thalamus and frontal cortex compared with patients without fatigue. Zhou et al. 17 found that fatigued patients exhibited changes in the thalamocortical system consisting of structural disconnections at DTI and hyperconnectivity at rs-fMRI, further supporting that fatigue could arise from increased functional connectivity as a compensation to the microstructural damage in the thalamocortical network.
Toward a unifying theory
Discrepancies between the above-mentioned studies could be referred to different patterns of (increased or reduced) activation/connectivity, in different parts of the thalamocortical network, at different stages of disease. In early stages, patients could compensate MS-related structural damage by plasticity mechanisms leading to overactivation of the cortical-subcortical network without experiencing any fatigue. Over time, functional reserve reduces, with an additional effort to maintain the overactivation of the network, leading to transient fatigue. Once plasticity is not able to compensate the reduced structural connectivity, functional connectivity drops and fatigue becomes chronically present. Not least, the structural and functional complexity of the thalamus has not been fully accounted, with most studies considering the thalamus as single region of interest. Preliminary data from volumetric 45 and fMRI studies 10 showed that different circuits or different parts of the same circuit within the basal ganglia-thalamuscortex network could be involved in the pathogenesis of different aspects of fatigue.
To the best of our knowledge, no longitudinal studies have examined patients over time to assess whether In healthy subjects, thalamus acts as a relay between different cortical and subcortical areas (a). In fatigued MS patients, fatigue can arise from an increase in the activity of the network, as a result of a compensatory mechanism that allows to maintain normal functioning but also produces fatigue (b). Alternatively, fatigue can arise from a global reduction in the activity of the network involving thalamus, basal ganglia, and cortex (c). RRMS (n = 12) PPMS (n = 3) HC (n = 15) mSDMT score (psychologist) ↑↑↑ Activation in thalamus, basal ganglia, and fronto-parietaloccipital cortex.
Neuropsychological fatigue, without self-reported fatigue. Small sample size.
DeLuca et al., 14 
J Neurol Sci
3T fMRI (task-switching task) RRMS (n = 9) PPMS (n = 1) SPMS (n = 1) HC (n = 11)
Self-reported cognitive fatigue (self-reported) ↑↑↑ Activation in prefrontal cortex, left postcentral gyrus, precuneus, precentral gyrus, inferior temporal gyrus, and declive of the cerebellum. ↓↓↓ Activation in the left superior frontal gyrus, right cuneus, and bilateral temporal regions (in the presence of microstructural impairment on DTI, with ↓↓↓ FA in the anterior internal capsule).
Neuropsychological fatigue, without self-reported fatigue.
HC not well matched. Small sample size.
Genova et al., 15 PLoS ONE fatigue-related brain patterns change over time. Thus, this hypothesis is solely based on the integration of the results from different studies that have investigated patients at different stages of MS. Accordingly, in patients with mild disability and short disease duration, fatigue is associated with microstructural damage in the thalamocortical pathway, compensated by hyperconnectivity at fMRI. 17 On the contrary, in patients with more advanced disease, the structural damage of the thalamocortical system is associated with decreased levels of functional connectivity. 23 In light of the extent of thalamic connections between different cortical and subcortical areas, thalamic pathology in MS could be secondary to a damage of afferent or efferent thalamic fibers. 24 According to this hypothesis, fatigue may be related to a non-specific, MS-induced disconnection between different brain regions, with thalamic abnormalities (atrophy and microstructural changes) being an epiphenomenon of MS pathology occurring elsewhere than thalamus. This hypothesis is supported by studies showing that fatigue is associated to a widespread microstructural change in the white matter 32, [50] [51] [52] or to a pathology of other structures different from thalamus, such as frontal 53 and primary somatosensory 54 cortex. However, widespread white matter involvement could be representative of more advanced MS, masking the relevance of specific structures (i.e. thalamus) in the pathogenesis of fatigue.
The specific role for thalamus in the pathogenesis of fatigue has been confirmed in both healthy subjects 55 and patients with different (and more focal) neurological diseases (e.g. stroke and traumatic brain injury). 56, 57 Indeed, a relatively small damage to the thalamic network, independently from the extent of diffuse brain involvement, could generate fatigue. Accordingly, in MS, microstructural abnormalities and atrophy in strategic brain regions (e.g. thalamus) have stronger associations with fatigue than measures of global brain damage, such as atrophy and lesion load. 9, 47 Not least, thalamus can be affected selectively, since the earliest stages of the disease, and independently from the extent of white matter involvement. 12
Conclusions, limitations, and future research
Neuroimaging studies have demonstrated that the thalamus is involved in the pathogenesis of MS-related fatigue, either as a cause or as a consequence of impaired cortical-subcortical networks. Though a number of brain regions contribute to the pathogenesis of fatigue, 53, 54, [58] [59] [60] thalamus is a strategic area and a relatively small disruption of its network can generate fatigue, independently from the extent of tissue involvement. 9, 61 In this review, we specifically focused on the results of neuroimaging studies supporting the role of the thalamic network in the pathophysiology of MS-related fatigue.
Future studies will have to clarify the role of thalamus within the pathogenesis of MS-related fatigue, overcoming the limitations of available data by (1) combining different neuroimaging and neurophysiological techniques (e.g. EEG-TMS and non-invasive brain stimulation) in the same sample to obtain multiparametric data; (2) investigating patients at different stages of disease (CIS and advanced progressive MS); (3) assessing whether thalamic impairment is primary or secondary to the damage of other structures outside of the thalamus (e.g. diffuse white matter damage) with a longitudinal design; (4) considering separately different thalamic nuclei and their connections; and (5) evaluating possible factors that contribute to fatigue pathogenesis and/or exacerbate its manifestations and perception (demographics, comorbidity, genetics, diet, exercise, depression, cognitive impairment, pain, and sleep disorders). [62] [63] [64] [65] The management of fatigue requires a multidisciplinary approach including both pharmacological and non-pharmacological interventions, but the evidence supporting their efficacy is still preliminary. Result heterogeneity could be due to methodological differences among studies in terms of sample (e.g. disease duration) and definition of fatigue, with very few studies including neuroimaging protocols. Clinical trials on MS-related fatigue treatments have sometimes requested MRI for baseline patients' stratification. [66] [67] [68] [69] Despite variations in thalamic activity were associated with fatigue development in an open-label study on interferon-beta-1a-treated patients, 13 so far, only one clinical trial (evaluating acupuncture and mindfulness for MS fatigue) included functional connectivity on fMRI as a tertiary outcome measure in a subgroup of patients. 70 Thus, a validated and reproducible set of measures for the thalamic network could be used to (1) identifying subgroups of fatigued patients that share common pathogenetic mechanisms; (2) quantifying objectively the subjective experience of fatigue; and (3) evaluating the efficacy of therapeutic interventions, ultimately leading to tailored pharmacological and non-pharmacological management of fatigue.
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